Astria Therapeutics, Inc. announced that it will share preclinical data for STAR-0215 in a presentation titled “Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215” at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky. The e-poster will be presented by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics, on November 13, 2022 at 12:05pm ET, and will be available to all registrants through the ACAAI ePoster Live System for the duration of the meeting and for six months following the meeting. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer.

The company's goal is to provide the most patient-friendly preventative treatment option for people living with HAE. Astria's Phase 1a clinical trial of STAR-0215 in healthy subjects is ongoing, with preliminary results anticipated by year-end.